Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle

Palantir Joins S&P 500: Alex Karp’s Unorthodox Path to Success

by Team Lumida
September 25, 2024
in Lifestyle
Reading Time: 2 mins read
A A
0
Palantir Joins S&P 500: Alex Karp’s Unorthodox Path to Success
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  1. Palantir joins the S&P 500, marking a significant milestone.
  2. CEO Alex Karp maintains a contentious relationship with Wall Street analysts.
  3. Palantir’s stock has surged 111% this year, outpacing the S&P’s 18% growth.

What Happened?

Palantir Technologies, under the leadership of Alex Karp, has officially joined the S&P 500, a significant milestone for the data analytics firm. The inclusion follows Palantir’s first profitable year in 2023 and the S&P’s relaxed rules on multiple-class shares.

Palantir’s stock has nearly quintupled since 2022, and the company’s market cap has exceeded $80 billion. Karp, now worth over $4 billion, has a complicated relationship with Wall Street, often expressing disdain for analysts and short sellers. Despite this, Palantir’s stock is up 111% this year, vastly outperforming the S&P 500’s 18% growth.

Why It Matters?

Joining the S&P 500 is a significant achievement for Palantir, as it solidifies the company’s standing among major U.S. corporations and will attract index-tracking funds and large institutional investors.

This milestone underscores Palantir’s successful transition to profitability and its crucial role in the burgeoning AI sector. However, skepticism remains among analysts about Palantir’s long-term growth potential and management’s controversial decisions, such as the ill-fated SPAC investments.

What’s Next?

As Palantir integrates into the S&P 500, expect increased scrutiny from institutional investors and analysts. The company’s ability to roll out its AI tools to corporate clients quickly will be crucial for sustaining its stock momentum.

Investors should monitor how Palantir addresses past missteps and engages with skeptical analysts. Additionally, Karp’s forthcoming book, “The Technological Republic,” may provide further insights into his vision for the company and its role in national security, potentially influencing investor sentiment.

Source: Bloomberg
Tags: Plantir
Previous Post

Ethereum ETFs Rebound Strongly: What Investors Need to Know

Next Post

China Challenges U.S. Over Potential Car Parts Ban – What’s at Stake?

Recommended For You

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
3 days ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
5 days ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
6 days ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
1 week ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
1 week ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
2 weeks ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
2 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
2 weeks ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
3 weeks ago

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
3 weeks ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more
Next Post
Premium Chinese Brands: Why Investors Are Losing Faith

China Challenges U.S. Over Potential Car Parts Ban – What's at Stake?

Metaverse Meets AI: A Game-Changer for Investors

Metaverse Meets AI: A Game-Changer for Investors

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

black and white star logo

SEC’s Gensler Hints at Summer Approval for Ether ETFs

June 14, 2024
September Rate Cut Likely as Job Market Risks Increase, Says Fed

Fed Moves to Quash DOJ Subpoenas in Powell Probe, Escalating Independence Standoff

February 27, 2026
Broadcom Inc. Q3 2024 Earnings Highlights: Significant revenue growth and strategic advancements in AI

Broadcom Inc. Q3 2024 Earnings Highlights: Significant revenue growth and strategic advancements in AI

September 6, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018